A guide to lymphedema

Expert Review of Dermatology

Volumn 2, Issue 6, 2007, Pages 741-752

  Gordon, Kristiana D ^a   Mortimer, Peter S ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Lymphatic dysfunction; Lymphedema; Primary lymphedema; Secondary lymphedema

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; COUMARIN; DAFLON; DAFLON500; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN V; STEROID; TROXERUTIN; UNCLASSIFIED DRUG; WHITFIELD OINTMENT;

ANKLE BRACHIAL INDEX; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BANDAGE; BREAST CANCER; BYPASS SURGERY; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL FEATURE; COMPRESSION THERAPY; DIFFERENTIAL DIAGNOSIS; DOPPLER ECHOGRAPHY; DRUG CHOICE; FILARIASIS; HUMAN; IMMOBILIZATION; INFECTION RISK; ISOTONIC EXERCISE; LIMB SWELLING; LYMPHADENECTOMY; LYMPHANGIOSARCOMA; LYMPHATIC DRAINAGE; LYMPHEDEMA; LYMPHOGRAPHY; LYMPHOSCINTIGRAPHY; MILROY DISEASE; MOTIVATION; MYCOSIS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROTECTIVE CLOTHING; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN CARE; SKIN MACERATION; SWELLING; TINEA PEDIS;

EID: 37349003385     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.6.741     Document Type: Review

References (79)

1. Moffatt CJ, Franks PJ, Doherty DC et al. Lymphoedema: an underestimated health problem. Q. J. Med. 96, 731-738 (2003).
2. Földi M. Insufficiency of lymph flow. In: Lymphangiology. Földi M, Casley-Smith JR (Eds). Schatteuer, Stuttgart, Germany, 195-213 (1983).
3. Tiwari A, Myint F, Hamilton G. Management of lower limb lymphoedema in the United Kingdom. Eur. J. Vasc. Endovasc. Surg. 31(3), 311-315 (2006).
4. Smeltzer DM, Stickler GB, Schirger A. Primary lymphedema in children and adolescents: a follow-up study and.review. Pediatrics 76 (2), 206-218 (1985).
5. Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. Q. J. Med. 98(5), 343-348 (2005).
6. Mortimer PS, Levick JR. Chronic peripheral oedema: the critical role of the lymphatic system. Clin. Med 4(5), 448-453 (2004).
7. Kubik S, Manestar M. Anatomy of the lymph capillaries and precollectors of the skin. In: The-Initial Lymphatics. Bollinger A, Partsch H, Wolfe JJN (Eds). Thieme, Stuttgart, Germany, 66-74 (1985).
8. De Long TG, Simmons RL. Role of lymphatic vessels in bacterial clearance from early soft tissue infection. Arch. Surg. 117, 123-128 (1982).
9. Yoffey JM, Courtice JM. Lymphatics, Lymph and the Lymphomyeloid Complex. New York Academic Press, NY, USA (1970).
10. Karkkainen MJ, Haiko P, Sainio K et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 5(1), 74-80 (2004).
11. Witte MH, Erickson R, Bernas M et al. Phenotypic and genotypic heterogeneity in familial Milroy lymphedema. Lymphology 31(4), 145-155 (1998).
12. Ferrell RE, Levinson KL, Esman JH et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum. Mol. Genet. 7(13), 2073-2078 (1998).
13. Evans AL, Brice G, Sotirova V et al. Mapping of primary congenital lymphedema to the 5q35.3 region. Am. J. Hum. Genet. 64(2), 547-555 (1999).
14. Karkkainen MJ, Ferrell RE, Lawrence EC et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25, 153-159 (2000).
15. Butler MG, Dagenais SL, Rockson SG et al. A novel VEGFR3 mutation causes Milroy disease. Am. J. Med. Genet. A. 143(11), 1212-1217 (2007).
16. Brice G, Mansour S, Bell R et al. Analysis of the phenotypic abnormalities in lymphoedema distichiasis syndrome in 74 patients with FOXC-2 mutations or linkage to 16q.24. J. Med. Genet. 39, 478-483 (2000).
17. Fang J, Dagenais SL, Erikson RP et al. Mutations in FOXC-2 (MFH-1) a forkhead family transcription factor are responsible for hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet. 67, 1382-1388 (2000).
18. Finegold DN, Kimak MA, Lawrence EC et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum. Mol. Genet. 10(11), 1185-1189 (2001).
19. Kriederman BM, Myloyde TL, Witte MH et al. FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum. Mol. Genet. 12(10), 1179-1185 (2003).
20. Sholto-Douglas-Vernon C, Bell R, Brice G et al. Lymphoedema-distichiasis and FOXC2, unreported mutations, de novo mutation estimate, families without coding mutations. Hum. Genet. 117(2-3), 238-242 (2005).
21. Meige H. Dystrophie oedemateuse héréditaire. Presse Méd. 6, 341-343 (1898).
22. Zhou XP, Hampel H, Thiele H et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndrome. Lancet 358, 210-211 (2001).
23. Mortimer PS. Disorders of lymphatic vessels. In: Rook's Textbook of Dermatology (7th Edition). Burns DA, Breathnach SM, Cox NH Griffiths CEM (Eds). Blackwell Publishing, Oxford, UK (2004).
24. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/ erysipelas of the lower leg: a series with community follow up. Br. J. Dermatol. 155(5), 947-950 (2006).
25. Stoberl C, Partsch H. Erysipelas and lymphoedema: hen or egg? Hautkrankheiten 62, 56-62 (1987).
26. de Almeida AB, Freedman DO. Epidemiology and immunopathology of bancroftian filariasis. Microbes Infect. 1(12), 1015-1022 (1999).
27. Kiely PD, Bland JM, Joseph AE et al. Upper limb lymphatic function in inflammatory arthritis. J. Rheumatol. 22, 214-217 (1995).
28. Nagai Y, Aoyama K, Endo Y et al. Lymphedema of the extremities developed as the initial manifestation of rheumatoid arthritis. Eur. J. Dermatol. 17(2), 175-176 (2007).
29. Sakorafas GH, Peros G, Cataliotti L et al. Lymphedema following axillary lymph node dissection for breast cancer. Surg. Oncol. 15(3), 153-165 (2006).
30. Sneddon I, Church R. Practical Dermatology (4th Edition). Edward Arnold, London, UK, 166 (1983).
31. Mortimer PS. Managing lymphoedema. Clin. Exp. Dermatol. 20, 98-106 (1995).
32. Stemmer R. Ein klinisches Zeichen zur Früh-und Differentialdiagnose des Lymphödems. Vasa 5, 261-262 (1976).
33. International Society of Lymphology. The diagnosis and treatment of peripheral lymphoedema. Consensus document of the International Society of Lymphology, Lymphology 36(2), 84-91 (2003).
34. Wheatley DC, Wastie ML, Whitaker SC et al. Lymphoscintigraphy and colour Doppler sonography in the assessment of leg oedema of unknown cause. Br. J. Radiol 69, 1117-1124 (1996).
35. Kinmonth JB. Lymphangiography in man. Clin. Sci. 11, 13-20 (1952).
36. Stewart G, Gaunt J. Croft DN et al. Isotope lymphography: a new method of investigating the role of lymphatics. Br. J. Surg. 72, 906-909 (1985).
37. Proby CM, Cane JN, Joseph AE et al. Investigation of the swollen limb with isotope lymphography. Br. J. Dermatol. 123, 29-38 (1990).
38. Lymphoedema Framework. Best practice for the management of lymphoedema, international consensus. MEP Ltd, London, UK (2006).
39. Allen EU, Hines EA. Lipoedema of the legs. A syndrome characterized by fat legs and orthostatic oedema. Proc. Staff Mayo Clinic 15, 1984-1987 (1940).
40. Wold LE, Hines EA, Allen EV. Lipoedema of the legs. Ann. Intern. Med. 34, 1243-1250 (1949).
41. Amann-Vesti BR, Franzeck UK, Bollinger A. Microlymphatic aneurysms in patients with lipedema. Lymphology 34(4), 170-175 (2001).
42. Harwood CA, Bull RH, Evans J et al. Lymphatic and venous function in lipoedema. Br. J. Dermatol. 134, 1-6 (1996).
43. Beninson J, Edelglass JW. Lipedema - the non-lymphatic masquerader. Angiology 35(8), 506-510 (1984).
44. Ketterings; C. Lipodystrophy and its treatment. Ann. Plast. Surg. 21(6), 536-543 (1988).
45. Jager G, Doller W, Roth R. Quality-of-life and body image impairments in patients with lymphedema. Lymphology 39(4), 193-200 (2006).
46. Pyszel A, Malyszczak K, Pyszel K et al. Disability, psychological distress and quality of life in breast cancer survivors with arm lymphoedema. Lymphology 39(4), 185-192 (2006).
47. Vignes S, Dupuy A. Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. J. Eur. Acad. Dermatol. Venereol. 20(7), 818-822 (2006).
48. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphoedema. Cancer 1, 64-81 (1948).
49. Laskas JJ, Shelley WB, Wood MG. Lymphangiosarcoma arising in congenital lymphedema. Arch. Dermatol. 111(1), 86-89 (1975).
50. Offori TW, Platt CC, Stephens M et al. Angiosarcoma in congenital hereditary lymphoedema (Milroy's disease) - diagnostic beacons and a review of the literature. Clin. Erp. Dermatol. 18(2), 174-177 (1993).
51. Dürr HR, Pellengahr C, Nerlich A et al. Stewart-Treves syndrome as a rare complication of a hereditary lymphedema. Vasa 33(1), 42-45 (2004).
52. Taghian A, de Vathaire F, Terrier P et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 21(2), 361-367 (1991).
53. Peyron N, Dandurand M, Guillot B. Malignant tumors as complications of lymphedema. J. Mal. Vasc. 18(4), 293-298 (1993).
54. Grobmyer SR, Daly JM, Glotzbach RE et al. Role of surgery in the management of postmastectomy extremity angiosarcoma (Stewart-Treves syndrome). J. Surg. Oncol. 73(3), 182-188 (2000).
55. Abraham JA, Hornicek FJ, Kaufman AM et al. Treatment and outcome of 82 patients with angiosarcoma. Ann. Surg. Oncol. 14(6), 1953-1967 (2007).
56. Benson PM, Pessoa CM, Lupton GP et al. Basal cell carcinomas arising in chronic lymphoedema. J. Dermatol. Surg. Oncol. 14, 781-783 (1988).
57. Epstein JL, Mendelsohn G. Squamous carcinoma of the foot arising in association with longstanding verrucous hyperplasia in a patient with congential lymphoedema. Cancer 54, 943-947 (1984).
58. Hills RJ, Ive FA. Cutaneous secondary follicular centre cell lymphoma in association with lymphoedema praecox. Br. J. Dermatol. 129, 186-189 (1993).
59. Bartal AH, Pinsky CM. Malignant melanoma appearing in a postmastectomy lymphoedematous arm: a novel association of double primary tumours. J. Surg. Oncol. 30, 16-18 (1985).
60. Merimsky O, Chaifchik S. Kaposi's sarcoma on a lymphoedematous arm following radical mastectomy. Tumori 78, 407-408 (1992).
61. Shreiber H, Barry FM, Russell WC et al. Stewart-Treves syndrome: a lethal complication of post mastectomy lymphoedema and regional immune deficiency. Arch. Surg. 114, 82-85 (1979).
62. Franks PJ, Moffatt CJ, Doherty DC et al. Assessment of health-related quality of life in patients with lymphedema of the lower limb. Wound Repair Regen. 14(2), 110-118 (2006).
63. Foldi E, Foldi M, Weissleder H. Conservative treatment of lymphoedema of the limbs. Angiology 36, 171-180 (1985).
64. Cheville AI, McGarvey CL, Petrek JA et al. Lymphedema management. Semin. Radiat. Oncol. 13(3), 290-301 (2003).
65. Badger CMA, Peacock JL, Mortimer PS. A randomized, controlled, parallel group clinical trial comparing multi-layer bandaging followed by hosiery versus hosiery alone in the treatment of patients with lymphoedema of the limb. Cancer 88, 2832-2837 (2000).
66. Clark M, Krimmel G. Lymphoedema and the construction and classification of compression hosiery. In: Lymphoedema Framework Template for Practice: Compression Hosiery in Lymphoedema. MEP Ltd, London, UK, 2-4 (2006).
67. Marston W, Vowden K. Compression therapy: a guide to safe practice. In: European Wound Management Association (EWMA). Position Document: Understanding Compression Therapy. MEP Ltd, London, UK, 11-17 (2003).
68. Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. Cancer 95(11), 2260-2267 (2002).
69. Ikomi F, Schmid-Schonbein GW Lymph transport in the skin. Clin. Dermatol. 13, 419-427 (1995).
70. Mortimer PS, Simmonds R, Rezvani M et al. Measurement of skin lymph flow by an isotope clearance technique: reliability, reproducibility effect of injection dynamics and lymph flow enhancement. J. Invest Dermatol. 95, 677-682 (1990).
71. Mortimer PS, Badger C, Clarke I, Pallett J. A double blind randomized, parallel group, placebo-controlled trial of O(-β hydroxyethyl)-rutosides in chronic arm oedema resulting from breast cancer treatment. Phlebology 10, 51-55 (1995).
72. Loprinzi CL, Kugler JW, Sloan JA et al. Lack of effect of coumarin in women with lymphoedema after treatment for breast cancer. N. Eng. J. Med. 340, 346-350 (1999).
73. Sistrunk WE. Modification of the operation for elephantiasis. JAMA 71, 800 (1918).
74. Charles H. A System of Treatment Latham, English TC (Eds). Churchill, London, UK (1912).
75. Gloviczki P. Principles of surgical treatment of chronic lymphoedema. Int Angiol. 18(1), 42-46 (1999).
76. Carrell T, Burnand K. Surgery and lymphoedema. In: Lympboedema. Twycross R, Jenns K, Todd J (Eds). Radcliffe Medical Press, Oxford, UK, 285-292 (2000).
77. Goldsmith HS, De los Santos R, Beattie GJ. Relief of chronic lymphoedema by omental transportation. Ann Surg. 166, 573-585 (1967).
78. Pugnaire MR. Linfangioplastia mesenterica en el tratamiento de las elephantiasis de las membros inferiors. Angiologia 20, 146-152 (1968).
79. Kinmonth JB. The Lympbatia: Surgery, Lymphography and Diseases af the Chyle and Lymph Systems. Edward Arnold, London, UK (1982).